Clinical features, functional consequences, and rescue pharmacology of missense GRID1 and GRID2 human variants
Human Molecular Genetics · 01.02.2024 · 33 (4) · 355-373
DOI: 10.1093/hmg/ddad188 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, online erschienen am 07.11.2023. Verfasst von James P Allen und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Chemical Biology, Emory University School of Medicine, 1510 Clifton Rd., Atlanta, GA 30322, United States. Hauptthemen laut MEDLINE: Central Nervous System, Receptors, Glutamate. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIGMS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
GRID1 and GRID2 encode the enigmatic GluD1 and GluD2 proteins, which form tetrameric receptors that play important roles in synapse organization and development of the central nervous system. Variation in these genes has been implicated in neurodevelopmental phenotypes. We evaluated GRID1 and GRID2 human variants from the literature, ClinVar, and clinical laboratories and found that many of these variants reside in intolerant domains, including the amino terminal domain of both GRID1 and GRID2. Other conserved regions, such as the M3 transmembrane domain, show different intolerance between GRID1 and GRID2. We introduced these variants into GluD1 and GluD2 cDNA and performed electrophysiological and biochemical assays to investigate the mechanisms of dysfunction of GRID1/2 variants. One variant in the GRID1 distal amino terminal domain resides at a position predicted to interact with Cbln2/Cbln4, and the variant disrupts complex formation between GluD1 and Cbln2, which could perturb its role in synapse organization. We also discovered that, like the lurcher mutation (GluD2-A654T), other rare variants in the GRID2 M3 domain create constitutively active receptors that share similar pathogenic phenotypes. We also found that the SCHEMA schizophrenia M3 variant GluD1-A650T produced constitutively active receptors. We tested a variety of compounds for their ability to inhibit constitutive currents of GluD receptor variants and found that pentamidine potently inhibited GluD2-T649A constitutive channels (IC50 50 nM). These results identify regions of intolerance to variation in the GRID genes, illustrate the functional consequences of GRID1 and GRID2 variants, and suggest how these receptors function normally and in disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Chemical Biology, Emory University School of Medicine, 1510 Clifton Rd., Atlanta, GA 30322, United States.
- Center for Functional Evaluation of Rare Variants (CFERV), Emory University School of Medicine, 1510 Clifton Rd., Atlanta, GA 30322, United States.
- Department of Human Genetics, Emory University School of Medicine, 615 Michael St., Atlanta GA 30322, United States.
- EGL Genetics, 2460 Mountain Industrial Blvd., Tucker, GA 30084, United States.
- Department of Biomedical Engineering, Georgia Institute of Technology, 313 Ferst Drive, Atlanta, GA 30332, United States.
- Department of Chemistry, Emory University School of Medicine, 1515 Dickey Dr, Atlanta, GA 30322, United States.
ORCID-Profile: Hongjie Yuan, Stephen F Traynelis
Förderung
- NIA NIH HHS
- NIGMS NIH HHS
- NCI NIH HHS
- NICHD NIH HHS
- NIH HHS
- NIAID NIH HHS
- NINDS NIH HHS
- NCATS NIH HHS
Zitieren
APA
Allen, J. P., Garber, K. B., Perszyk, R., Khayat, C. T., Kell, S. A., Kaneko, M., Quindipan, C., Saitta, S., Ladda, R. L., Hewson, S., Inbar-Feigenberg, M., Prasad, C., Prasad, A. N., Olewiler, L., Mu, W., Rosenthal, L. S., Scala, M., Striano, P., Zara, F., …, & Traynelis, S. F. (2024). Clinical features, functional consequences, and rescue pharmacology of missense GRID1 and GRID2 human variants. Human Molecular Genetics, 33(4), 355-373. https://doi.org/10.1093/hmg/ddad188
Vancouver
Allen JP, Garber KB, Perszyk R, Khayat CT, Kell SA, Kaneko M, et al. Clinical features, functional consequences, and rescue pharmacology of missense GRID1 and GRID2 human variants. Human Molecular Genetics. 2024;33(4):355-373. doi:10.1093/hmg/ddad188
BibTeX
@article{Allen2024,
author = {Allen, James P and Garber, Kathryn B and Perszyk, Riley and Khayat, Cara T and Kell, Steven A and Kaneko, Maki and Quindipan, Catherine and Saitta, Sulagna and Ladda, Roger L and Hewson, Stacy and Inbar-Feigenberg, Michal and Prasad, Chitra and Prasad, Asuri N and Olewiler, Leah and Mu, Weiyi and Rosenthal, Liana S and Scala, Marcello and Striano, Pasquale and Zara, Federico and McCullock, Tyler W and Jauss, Robin-Tobias and Lemke, Johannes R and MacLean, David M and Zhu, Cheng and Yuan, Hongjie and Myers, Scott J and Traynelis, Stephen F},
title = {Clinical features, functional consequences, and rescue pharmacology of missense GRID1 and GRID2 human variants},
journal = {Human Molecular Genetics},
year = {2024},
volume = {33},
number = {4},
pages = {355--373},
doi = {10.1093/hmg/ddad188}
}
EUVIMED